Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
are the known incretin hormones in humans, released predominantly from the …

An increase in the rates of morbidity and mortality associated with diabetic complications is a
global concern. Glycemic control is important to prevent the development and progression of …

Introduction The aim of this study was to assess the utility of [Lys40 (Ahx-HYNIC-
99mTc/EDDA) NH2]-exendin-4 scintigraphy in the management of patients with …

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are the most recent addition to the
therapeutic options available for the treatment of type 2 diabetes and became available after …

Background Sleeve gastrectomy is indicated for the treatment of obesity and related co-
morbidity including diabetes. The dynamic changes in insulin secretion and sensitivity after …

Background: Only about half of patients with type 2 diabetes treated with antihyperglycemic
drugs achieve glycemic control (HbA1c< 7%), most commonly due to poor treatment …

Objective To synthesize current evidence of the impact of Glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) on hypoglycemia, treatment discontinuation and glycemic level in …

Background To investigate the ameliorating effect of sitagliptin, a dipeptidyl peptidase-4
inhibitor, on blood glucose control in patients with type 2 diabetes mellitus who were …

Glucagon family of peptide hormones is a group of structurally related brain-gut peptides
that exert their pleiotropic actions through interactions with unique members of class B1 G …

Abstract Background and Objective Once-weekly glucagon-like peptide-1 receptor agonists
(GLP-1RAs) are a novel class of injectable antidiabetic drugs. Previous studies indicated …